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Background
The adenosine triphosphate-binding cassette transporters
P-glycoprotein (Pgp) and breast cancer resistance protein
(BCRP) restrict absorption and body distribution and pro-
mote excretion of several clinically used drugs. Tariquidar
(XR9576) is a potent third-generation dual Pgp and BCRP
inhibitor, which is currently tested in clinical trials to over-
come chemoresistance of tumors and to enhance brain
distribution of Pgp/BCRP substrate drugs. We performed
a positron emission tomography (PET) microdosing study
with carbon-11-labelled tariquidar ([11C]tariquidar) which
aimed at assessing the brain distribution of [11C]tariquidar
in healthy volunteers.
Methods
Six healthy subjects received an i.v. bolus injection of
approximately 400 MBq of [11C]tariquidar containing less
than 30 µg of unlabelled tariquidar. Then, dynamic brain
PET scans and arterial blood sampling were performed.
Radiolabelled metabolites of [11C]tariquidar in plasma
were measured with a solid-phase extraction/HPLC assay.
Brain activity uptake was expressed as the ratio of the area
under the whole brain grey matter time-activity curve to
the area under the plasma time-activity curve from time
0 to 60 min (AUC0–60 brain/AUC0–60 plasma).
Results
Brain activity uptake was low after injection of [11C]tari-
quidar with a mean AUC0–60 brain/AUC0–60 plasma of
0.14 ± 0.03. At 60 min after radiotracer injection, 78 ±
12% of total radioactivity in plasma was in the form of
unchanged parent radiotracer. Less than 1% of the total
injected dose excreted in urine over 90 min.
Conclusions
Low brain uptake of radioactivity is consistent with tari-
quidar being, at microdoses, a dual substrate of Pgp and
BCRP. [11C]Tariquidar PET after inhibition of Pgp with
unlabelled tariquidar may be a promising approach to
selectively assess BCRP function at the human blood-brain
barrier.
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